Healthy Volunteers Clinical Trial
— CamOptOfficial title:
Evaluation of Lung Volume Under Nasal High Flow With a Time of Flight Camera
| Verified date | November 2019 |
| Source | University Hospital, Brest |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The effectiveness of Nasal High Flow therapy (NHF), in comparison with conventional oxygen
therapy, is based on Positive Expiratory Pressure (PEP) and washout of dead space.
Many authors have shown that peak expiratory pressure, expiratory plateau pressure, mean
upper airway pressure and lung volume were significantly increased. It depends mainly on gas
flow and mouth closure.
First, "Groves"showed in 2007 that mouth opening could vary nasopharyngeal pressure from 2.7
to 7.4 cmH20 to 60 L / min, like Parke did in 2009, with a pressure of 1.2 at 2.7 cmH2O at 35
L / min.
Then, "Parke" showed in 2011 and 2015, a nasopharyngeal pressure changing from 2.7 to 11.9
cmH20 by varying the flow rate from 30 to 100 L / min. "Bräunlich" also showed concordant
results in 2018, from 1.6 to 2.3 cmH2O, changing flow rates from 20 to 40 L / min. "Corley"
in 2011 found a pressure from -0.3 to 2.7 by passing from ambient air to high flow. "Okuda
and Mauri's" work in 2017 on oesophageal pressures also contributed to this.
In addition, it has been proved that the Tidal Volume (TV) is proportional to the flow
delivered. These measurements were carried out by impedancemetry, the results of which were
extrapolated to Vt. Thus "Okuda" evaluated it at 685mL in ambient air and 968mL at 50L / min.
In 2016, "Fraser" highlighted a TV increasing from 400 to 500 mL by increasing the flow rate
to 30 L / min. "Parke" in 2015 described an exponential End Expiratory Lung Impedence (EELI)
proportional to the flow rate, as did "Riera" in 2013 with a ratio of 1.26 between ambient
air and NHF at 40 L / min, and "Corley" in 2011 (ratio of 1.25).
Actualy, Time-of-Flight (ToF) cameras, such as Kinect v2®, are increasingly used in the
medical field, particularly to characterize respiratory movement.
Various authors have shown a good correlation between the values of TV obtained by spirometry
(reference method) and those obtained with ToF camera. A study led in 2018, by "S. Nazir" in
the Department of "Réanimation Médicale" at the University Hospital of Brest, evaluated the
average errors less than 46mL, with 76% of measurements having an error less than 50 mL,
which corresponds to the clinical limit.
Now having a non-invasive, safe, simple, reproducible, inexpensive, and allowing evaluation
in clinical situations method ; the use of a Time-of-Flight camera to evaluate the breathing
and its various parameters, is indicated.
In this innovative study, never performed in different respiratory conditions in vigilant
patients with NHF, the lung volume will be evaluated by a Time-of-Flight camera.
Different clinical situations, and the different parameters influencing it, will be observed
and compared with the results of previous studies.
These situations will be simulations ranging from a physiological state to an acute
respiratory distress.
| Status | Completed |
| Enrollment | 10 |
| Est. completion date | November 7, 2019 |
| Est. primary completion date | November 7, 2019 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Healthy and Major Volunteers Exclusion Criteria: - Nasopharyngeal obstruction, facial trauma, or other contraindication to the use of Nasal High Flow, pregnant woman, major incompetent, lack of consent. |
| Country | Name | City | State |
|---|---|---|---|
| France | CHRU de Brest | Brest |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Brest |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Evaluation of the pulmonary volume change | Changes on the pulmonary volume in different situations during 3 hours. | 3 hours |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
| Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
| Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
| Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
| Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
| Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
| Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
| Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
| Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
| Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
| Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
| Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
| Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
| Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
| Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
| Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
| Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |